Evidence map›Paper›PMID 41261852›Full record

ArticleNucleic acids research2025

KlebPhaCol: a community-driven resource for Klebsiella research identified a novel phage family.

Daniela Rothschild-Rodriguez, Kai S Lambon, Simran Krishnakant Kushwaha, Sofya K Garushyants, Moritz Ertelt, Agnieszka Latka, Ana Rita Costa, Anna Mantzouratou, Claire King, Dimitri Boeckaerts and 21 more

Abstract read
In one paragraph

Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Daniela Rothschild-RodriguezSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, Hampshire, United Kingdom.
Kai S LambonSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, Hampshire, United Kingdom.
Simran Krishnakant KushwahaSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, Hampshire, United Kingdom.
Sofya K GarushyantsComputational Biology Branch, Division of Intramural Research, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, United States.
Moritz ErteltFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research IIP, Munich 60596, Germany.
Agnieszka LatkaDepartment of Biotechnology, Ghent University, Ghent 9000, Belgium.
Ana Rita CostaDepartment of Bionanoscience, Delft University of Technology, Delft 2629 HZ, The Netherlands.
Anna MantzouratouLife and Environmental Sciences, Bournemouth University, Bournemouth BH12 5BB, United Kingdom.
Claire KingSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, Hampshire, United Kingdom.
Dimitri BoeckaertsDepartment of Biotechnology, Ghent University, Ghent 9000, Belgium.
Elizabeth SheridanLife and Environmental Sciences, Bournemouth University, Bournemouth BH12 5BB, United Kingdom.
Eugene V KooninComputational Biology Branch, Division of Intramural Research, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, United States.ORCID 0000-0003-3943-8299
Francesca MerrickSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, Hampshire, United Kingdom.
Francis DrobniewskiLife and Environmental Sciences, Bournemouth University, Bournemouth BH12 5BB, United Kingdom.
Ilaria De AngelisDepartment of Biotechnology, Ghent University, Ghent 9000, Belgium.
Kordo SaeedDepartment of Infection, Microbiology, University Hospital Southampton, Southampton SO16 6YD, United Kingdom.
Macy MartinSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, Hampshire, United Kingdom.
J Mark SuttonUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Matthew E WandUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Michael AndrewSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, Hampshire, United Kingdom.
Morgen HedgesSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, Hampshire, United Kingdom.
Stan J J BrounsDepartment of Bionanoscience, Delft University of Technology, Delft 2629 HZ, The Netherlands.
Pieter-Jan HaasMedical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht 3584 CX, Netherlands.ORCID 0000-0002-1127-095X
Sophie T LawsonUnited Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.
Stephen M E FordhamLife and Environmental Sciences, Bournemouth University, Bournemouth BH12 5BB, United Kingdom.
Yan-Jiun LeeResearch Department, New England Biolabs, Inc., Ipswich, Massachusets 01938, United States.
Yi WuSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, Hampshire, United Kingdom.
Yves BriersDepartment of Biotechnology, Ghent University, Ghent 9000, Belgium.ORCID 0000-0001-7723-1040
Peter BraunFraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research IIP, Munich 60596, Germany.
Peter R WeigeleResearch Department, New England Biolabs, Inc., Ipswich, Massachusets 01938, United States.ORCID 0000-0003-3696-4541
Franklin L NobregaSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, Hampshire, United Kingdom.ORCID 0000-0002-8238-1083

Funding

Bowel Research UKEuropean Research Council CoG 10100322Fullbright postdoctoral fellowshipNational Library of Institutes of HealthNIHR Biomedical Research Centre Postdoctoral Bridging FellowshipOpen Innovation in AMR platform 111742Open Innovation in AMR platform 111743Research Foundation-Flanders 1120125NResearch Foundation-Flanders 1251224NSouth Coast Biosciences Doctoral Training Partnership BBSRC BB/T008768/1Wessex Medical Trust Innovation AB03
6 · The paper itself

Abstract

The growing threat of multidrug-resistant Klebsiella pneumoniae, coupled with its role in gut colonisation, has intensified the search for new treatments, including bacteriophage therapy. Despite increasing documentation of Klebsiella-targeting phages, clinical applications remain limited, with key phage-bacteria interactions still poorly understood. A major obstacle is fragmented access to well-characterised phage-bacteria pairings, restricting the collective advancement of therapeutic and mechanistic insights. To address this gap, we created the Klebsiella Phage Collection (KlebPhaCol), an open resource comprising 52 phages and 74 Klebsiella isolates, characterised at phenotypic and genomic levels. These phages span six families-including a novel family, Felixviridae, associated with the human gut-and target 20 sequence types (including ST258, ST11, and ST14) and 19 capsular-locus types (including KL1 and KL2), across 6 Klebsiella species. Freely accessible at www.klebphacol.org, KlebPhaCol invites the scientific community to both use and contribute to this resource, fostering collaborative research and a deeper understanding of Klebsiella-phage interactions beyond therapeutic use.

Indexed as

BacteriophagesKlebsiellaKlebsiella pneumoniaeGenome, ViralHumansKlebsiella InfectionsPhylogeny

Identifiers

PMID41261852
PMCPMC12629751

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.